Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 05, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Executive Supplemental Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Specific transaction details include:
- Transaction Type: Increase in interests in Ordinary Share ADRs via the Annual Investment Plan feature.
- Trigger Event: Re-investment of the dividend paid to shareholders on January 04, 2007.
- Share Price: $54.72 per share.
Material Changes
The filing reports changes in shareholdings for the following individuals due to the dividend re-investment:
- Dr. JP Garnier: 327.53 shares
- Dr. F Calhoun: 337.60 shares
- Dr. D Pulman: 17.65 shares
- Mr. D Stout: 268.72 shares
No material changes to the company's financial position or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification pursuant to Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the dividend payment date of January 04, 2007, and the re-investment price of $54.72 per share.
- Confirm the updated shareholdings of the named directors (Garnier, Calhoun, Pulman, Stout) in subsequent filings.
- Note that this filing contains no operational or financial performance data for the period.